Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityConvertible DebtCurrent AssetsCurrent Deferred RevenueCurrent LeasesCurrent TaxesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsMinority InterestNon-Current AssetsNon-Current DebtNon-Current Deffered RevenueOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetRetained EarningsShareholder's EquityShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

BridgeBio Pharma (BBIO) Accumulated Expenses: 2019-2024

Historic Accumulated Expenses for BridgeBio Pharma (BBIO) over the last 6 years, with Dec 2024 value amounting to $58.3 million.

  • BridgeBio Pharma's Accumulated Expenses rose 28.97% to $56.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $56.2 million, marking a year-over-year increase of 28.97%. This contributed to the annual value of $58.3 million for FY2024, which is 1.67% up from last year.
  • Latest data reveals that BridgeBio Pharma reported Accumulated Expenses of $58.3 million as of FY2024, which was up 1.67% from $57.4 million recorded in FY2023.
  • BridgeBio Pharma's Accumulated Expenses' 5-year high stood at $58.3 million during FY2024, with a 5-year trough of $29.7 million in FY2020.
  • Its 3-year average for Accumulated Expenses is $49.0 million, with a median of $57.4 million in 2023.
  • In the last 5 years, BridgeBio Pharma's Accumulated Expenses spiked by 122.89% in 2020 and then fell by 15.62% in 2022.
  • Over the past 5 years, BridgeBio Pharma's Accumulated Expenses (Yearly) stood at $29.7 million in 2020, then increased by 24.79% to $37.0 million in 2021, then dropped by 15.62% to $31.3 million in 2022, then surged by 83.55% to $57.4 million in 2023, then increased by 1.67% to $58.3 million in 2024.